Table 5 Case reports of omalizumab for the management of ICEP
From: Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review
Doses | Number of participants | Duration of follow-up after biological | Age/sex/Comorbidities | Outcomes | Case report reference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory symptoms | Relapses | Systemic corticosteroid | Radiological findings | Lung function | Quality of life | Adverse events | |||||
150Â mg every 4 weeks. Mepolizumab 100Â mg every 4 weeks | 1 | 12 months 18 months | Female, 48 years old. Asthma, chronic rhinosinusitis without polyps. Diagnosis by biopsy | Partial improvement with Omalizumab. No symptoms after 4 weeks of initiation of mepolizumab | None after start | Reduction of the dose, but allows to suspend it. Allows reduction and suspension 24 months after starting mepolizumab | No improvement during the 12 months with Omalizumab Complete resolution 14 months after the start of mepolizumab | No improvement during the 12 months with Omalizumab Improvement 3 months after starting mepolizumab, normalization at 12 months | Not described | No adverse events during handling | Lin et al. 2019 [49]. |
300Â mg every 2 weeks for 9 months. Dose per total IgE level. 225Â mg every 2 weeks for 3 months. Dose per total IgE level. Then, 150 every 2 weeks for 2 months | 2 | 33 months 20 months | Case 1: Male, 17 years old. Asthma, sensitization to aeroallergens. Case 2: Male, 19 years old. Asthma, sensitization to aeroallergens | Improvement after the start, being complete at 9 months. Complete improvement at one month | No relapses after initiation No relapses after initiation | Allows descent and suspension 5 months after initiation. Allows descent with suspension one month from the start | Improvement at 5 months Improvement at 5 months | Not described Not described | Not described Not described | No adverse events during handling No adverse events during handling | Shin et al. 2012 [50]. |
300Â mg every 2 weeks. Dose per total IgE level 429 IU/mL. Treatment for 18 months. Restart after relapse at the same dose for 24 months | 1 | 69 months | Female, 68 years old. Osteoporosis, aeroallergen sensitization | Improvement after the start. a Relapse 10 months after withdrawal, with improvement a few weeks after initiation. a After stopping it, without relapses at 17 months | 10 months after the withdrawal so it is restarted, without relapses 2 years after the restart | Descent after a few weeks. It requires restart after relapse, tolerating descent and withdrawal. a | Complete normalization at 17 months. After relapse, normalization at 2 years after restart. | Not described | Not described | Not described | Nehme et al. 2022 [51]. |
Omalizumab (dose not mentioned) | 1 | Not described | Female, 55 years old. Allergic asthma, rhinoconjunctivitis. On lung transplant list | Improvement after the start. Withdrawal from transplant list | None after start | Withdrawal at 24 months | Not described | Not described | Not described | Not described | Laviña Soriano et al. 2017 [52]. |
300Â mg every 4 weeks for 18 months, then decrease 50% every 6 months until discontinuation | 1 | 45 months | Female, 36 years old. Asthma Depression and steroid amenorrhea | Improvement after the start. a | None after the start. No relapses after 15 months of finishing the treatment | Tolerated descent and suspension at the 4th week | Resolution after treatment a | Not described | Not described | No adverse events during handling | Kaya & Tozkoparan 2012 [53]. Domingo & Pomares 2013 [54]. |